JP2019068852A5 - - Google Patents

Download PDF

Info

Publication number
JP2019068852A5
JP2019068852A5 JP2019006734A JP2019006734A JP2019068852A5 JP 2019068852 A5 JP2019068852 A5 JP 2019068852A5 JP 2019006734 A JP2019006734 A JP 2019006734A JP 2019006734 A JP2019006734 A JP 2019006734A JP 2019068852 A5 JP2019068852 A5 JP 2019068852A5
Authority
JP
Japan
Prior art keywords
vector
polypeptide
vaccine composition
protein
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019006734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019068852A (ja
JP6748240B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019068852A publication Critical patent/JP2019068852A/ja
Publication of JP2019068852A5 publication Critical patent/JP2019068852A5/ja
Application granted granted Critical
Publication of JP6748240B2 publication Critical patent/JP6748240B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019006734A 2015-08-20 2019-01-18 治療用ｈｐｖ１８ワクチン Expired - Fee Related JP6748240B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15181791 2015-08-20
EP15181791.3 2015-08-20
EP16156334 2016-02-18
EP16156334.1 2016-02-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018509566A Division JP6470872B2 (ja) 2015-08-20 2016-08-18 治療用ｈｐｖ１８ワクチン

Publications (3)

Publication Number Publication Date
JP2019068852A JP2019068852A (ja) 2019-05-09
JP2019068852A5 true JP2019068852A5 (enExample) 2019-10-03
JP6748240B2 JP6748240B2 (ja) 2020-08-26

Family

ID=56787465

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018509566A Expired - Fee Related JP6470872B2 (ja) 2015-08-20 2016-08-18 治療用ｈｐｖ１８ワクチン
JP2019006734A Expired - Fee Related JP6748240B2 (ja) 2015-08-20 2019-01-18 治療用ｈｐｖ１８ワクチン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018509566A Expired - Fee Related JP6470872B2 (ja) 2015-08-20 2016-08-18 治療用ｈｐｖ１８ワクチン

Country Status (21)

Country Link
US (3) US9790256B2 (enExample)
EP (1) EP3337500A1 (enExample)
JP (2) JP6470872B2 (enExample)
KR (1) KR20180042295A (enExample)
CN (1) CN107921110B (enExample)
AU (2) AU2016309743B2 (enExample)
BR (1) BR112018003019A2 (enExample)
CA (1) CA2995740A1 (enExample)
CL (1) CL2018000432A1 (enExample)
CO (1) CO2018001623A2 (enExample)
EA (1) EA037295B1 (enExample)
HK (1) HK1252967A1 (enExample)
IL (1) IL257604A (enExample)
JO (1) JO3765B1 (enExample)
MX (1) MX2018002106A (enExample)
MY (1) MY195389A (enExample)
SA (1) SA518390954B1 (enExample)
SG (1) SG10202001501QA (enExample)
TW (1) TWI744246B (enExample)
WO (1) WO2017029360A1 (enExample)
ZA (2) ZA201801119B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015341926B2 (en) 2014-11-04 2018-09-27 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
EP3337500A1 (en) 2015-08-20 2018-06-27 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines
CA3021341A1 (en) * 2016-05-02 2017-11-09 Janssen Vaccine & Prevention B.V. Therapeutic hpv vaccine combinations
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
MY201967A (en) * 2017-09-23 2024-03-27 Boehringer Ingelheim Pharma Paramyxoviridae expression system
EP3461497A1 (en) * 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
WO2019151760A1 (ko) * 2018-02-02 2019-08-08 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
CN112437684A (zh) * 2018-07-20 2021-03-02 扬森疫苗与预防公司 以提高的生产率表达寨卡抗原的重组腺病毒载体
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
JP7732977B2 (ja) 2019-09-20 2025-09-02 トランスジーン Ｈｐｖポリペプチドおよびｉｌ－２をコードするポックスウイルスと抗ｐｄ－ｌ１抗体の組合せ
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
WO2021202949A2 (en) * 2020-04-02 2021-10-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia
JP2023521194A (ja) 2020-04-13 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ及びｓｔｅａｐ１ワクチン並びにそれらの使用
AU2021270777A1 (en) 2020-05-12 2022-11-10 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4267605A2 (en) 2020-12-23 2023-11-01 Janssen Biotech, Inc. Neoantigen peptide mimics
WO2023070109A1 (en) * 2021-10-22 2023-04-27 Inovio Pharmaceuticals, Inc. Compositions and methods for treating anal high-grade squamous intraepithelial lesion (hsil)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP0784690B1 (en) 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
EP0973866A4 (en) 1997-03-04 2000-04-19 Baxter Int ADENOVIRUS E1-COMPLEMENTING CELL LINES
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
PT1816205E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante baseado no serótipo 48 (ad48)
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
WO2002028165A2 (en) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
EP1385946B1 (en) 2001-05-01 2009-12-23 National Research Council Of Canada A system for inducible expression in eukaryotic cells
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CA2552508A1 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
JP2007522814A (ja) 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
JP5291341B2 (ja) 2004-11-08 2013-09-18 クロマジェニックス ベー ヴェー タンパク質を高レベルで発現する宿主細胞の選定
CN1796403B (zh) * 2004-12-22 2010-04-28 三峡大学 用于多型人乳头瘤病毒感染防治的多肽和疫苗
WO2007073513A2 (en) 2005-11-10 2007-06-28 Genvec, Inc. Method for propagating adenoviral vectors encoding inhibitory gene products
AU2007220988B2 (en) 2006-02-28 2010-06-03 Vaxart, Inc Chimeric adenoviral vectors
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
CN101100672B (zh) * 2007-06-06 2010-05-26 曾毅 经修饰的hpv e6-e7融合基因及其编码蛋白
DE102008010954A1 (de) * 2008-02-25 2009-08-27 Cichon, Günter, Prof.Dr. DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
CN101591646B (zh) * 2008-05-27 2012-05-30 清华大学深圳研究生院 一种治疗人宫颈癌的树突状细胞疫苗
CN102203242B (zh) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
EP2536829B1 (en) 2010-02-15 2016-04-06 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2601968A1 (en) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
TR201908199T4 (tr) * 2011-12-21 2019-06-21 Vaccibody As HPV'ye karşı aşılar.
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
CN103864936B (zh) * 2012-12-11 2018-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv18型l2ne7e6融合蛋白基因、表达载体、方法、菌株和用途
AU2015341926B2 (en) 2014-11-04 2018-09-27 Janssen Vaccines & Prevention B.V. Therapeutic HPV16 vaccines
EP3337500A1 (en) 2015-08-20 2018-06-27 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines

Similar Documents

Publication Publication Date Title
JP2019068852A5 (enExample)
JP2018148890A5 (enExample)
Frazer Prevention of cervical cancer through papillomavirus vaccination
US8337859B2 (en) Vectors for multiple gene expression
KR101636575B1 (ko) 유두종바이러스 백신
RU2008145712A (ru) Вакцина против папилломовирусной инфекции на основе вируса папиломы человека впч-16
JP2020519614A5 (enExample)
JP2010516287A5 (enExample)
Campo et al. Papillomavirus prophylactic vaccines: established successes, new approaches
US20100055069A1 (en) Hpv-18-based papillomavirus vaccines
CN107080833A (zh) 作为广谱人类乳头状瘤病毒（hpv）疫苗的乳头状瘤病毒样颗粒（vlp）
JP2019514943A5 (enExample)
RU2005109155A (ru) Днк-вакцина, кодирующая по меньшей мере два неструктурных ранних белка вируса папилломы
JP2002532434A5 (enExample)
JP2006516386A5 (enExample)
AbouZaid Oncogenic Viruses and Cancer: A Review of Literature on Their Global Burden
US6926897B1 (en) Medicament for the avoidance or treatment of papillomavirus-specific tumour
US20250041399A1 (en) Cmv-based human papillomavirus vaccines
ES2370674T3 (es) Polipéptido e2 de papilomavirus utilizado para la vacunación.
Talbot et al. Viruses and cancer
Moscarini et al. Anti human papillomavirus vaccine: The checkmate to human papillomavirus?
Guo et al. Development Status and trend of HPV vaccine
CN119736337A (zh) Matv51重组腺病毒载体、应用、制备方法及hpv16/18/52治疗性疫苗
HK1135731B (en) Vectors for multiple gene expression
JPWO2023070109A5 (enExample)